PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11408373-2	2001	The aim of the present investigation was to study the contribution of CYP2C9 and CYP3A4 in losartan oxidation in vitro and to evaluate the role of CYP2C9 polymorphism.	Losartan	91-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87	
25424246-8	2015	These findings suggest that 50 mumol/L of losartan inhibits both CYP2C8 and CYP3A4 in HLMs.	Losartan	42-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82	
20716633-4	2010	CYP1A2, CYP2D6, CYP2C9, and CYP3A4 enzyme activities were measured by the metabolism of caffeine, dextromethorphan, losartan, and buspirone, respectively.	Losartan	116-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34	
10877007-6	2000	Losartan and irbesartan inhibited CYP1A2- and CYP3A4-associated activities (ethoxyresorufin O-deethylation and testosterone 6beta-hydroxylation) with relatively weak affinities (IC50 values between 200 microM and 500 microM).	Losartan	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-52	
11054425-2	2001	In the present study, we observed that alpha-naphthoflavone (alpha-NF) exhibited a differential effect on CYP3A4-mediated product formation as shown by an increase and decrease, respectively, of the carboxylic acid (P(2)) and omega-3-hydroxylated (P(1)) metabolites of losartan, while losartan was found to be an inhibitor of the formation of the 5,6-epoxide of alpha-NF.	Losartan	269-277	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112	
11054425-2	2001	In the present study, we observed that alpha-naphthoflavone (alpha-NF) exhibited a differential effect on CYP3A4-mediated product formation as shown by an increase and decrease, respectively, of the carboxylic acid (P(2)) and omega-3-hydroxylated (P(1)) metabolites of losartan, while losartan was found to be an inhibitor of the formation of the 5,6-epoxide of alpha-NF.	Losartan	285-293	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112	
10877007-9	2000	Losartan and irbesartan have modest affinity for CYP1A2 and CYP3A4.	Losartan	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66	
9542475-1	1998	BACKGROUND: Losartan is metabolized by CYP2C9 and CYP3A4 to an active metabolite, E3174, which has greater antihypertensive activity than the parent compound.	Losartan	12-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56	
10197301-1	1999	Losartan is an angiotensin II receptor antagonist that is metabolized by CYP2C9 and CYP3A4 to a more potent antihypertensive metabolite, E3174.	Losartan	0-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90	
10197301-8	1999	Inhibition of losartan metabolism appears to require both CYP2C9 and CYP3A4 inhibition.	Losartan	14-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75	
9542475-12	1998	On the basis of the minimal inhibitory effects observed with erythromycin, CYP3A4 appears to play a minor role in the in vivo metabolism of losartan to E3174.	Losartan	140-148	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81	
7736913-9	1995	It was then demonstrated that microsomes containing either recombinant human liver CYP2C9 or CYP3A4 were capable of oxidizing both losartan and the aldehyde E3179 to the carboxylic acid E3174.	Losartan	131-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99	
9551703-1	1998	OBJECTIVE: Losartan is metabolised to its active metabolite E-3174 by CYP2C9 and CYP3A4 in vitro.	Losartan	11-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87	
7736913-10	1995	Subsequently, it was shown that rabbit anti-CYP2C9 and anti-CYP3A3/4 inhibited the oxidation of losartan to E3174 in incubations with human liver microsomes.	Losartan	96-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66	
31058419-2	2019	Amlodipine is mainly metabolized by cytochrome P450 (CYP) 3A4, whereas losartan is metabolized by CYP2C9 and CYP3A4.	Losartan	71-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-115	
27474842-3	2016	The aim of this study is to describe the distribution of CYP2C9*2, CYP2C9*3, CYP3A4*22 and CYP3A5*3 defective alleles, according to losartan tolerance in paediatric Marfan patients.	Losartan	132-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83	
27934636-7	2017	Only using the RAF derived from testosterone for CYP3A4 produced the expected CYP2C9 contribution of 72%-87% and 47%-69% for metabolism of losartan and meloxicam, respectively.	Losartan	139-147	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55	
26806573-0	2016	Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9.	Losartan	76-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-146	
27216792-6	2016	RESULTS: Based on the literatures published, it has been demonstrated that pharmacokinetic interactions of losartan with other agents are mainly via CYP2C9- and CYP3A4-mediated, the role played by CYP enzyme system in the metabolism of valsartan, candesartan, irbesartan, and azilsartan appears modest, and cytochrome P450 system has no influence on the metabolism of telmisartan, eprosartan, olmesartan.	Losartan	107-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-167